Clinical Trials Logo
  1. Home
  2. Adrenocortical Carcinoma
  3. NCT05660889

Adrenal Vein Sampling as a Tool to Identify Biomarkers That Aid the Diagnosis of Adrenocortical Carcinoma — AVS for ACC  

Adrenocortical Carcinoma Clinical Trial

Official title:
Adrenal Vein Sampling as a Tool to Identify Biomarkers That Aid the Diagnosis of Adrenocortical Carcinoma

Clinical Trial Summary

The goal of this observational pilot study is to explore whether we can identify biomarkers predictive for the diagnosis of adrenocortical carcinoma in blood. Five participants who are suspected to have adrenocortical carcinoma will undergo an adrenal vein sampling in order to obtain a blood sample from the adrenal vein. This blood sample will be analyzed and compared to blood samples taken from the adrenal vein of 20 control patients, which are patients who do not have adrenocortical carcinoma. The blood samples of the control patients will be drawn during routine medical care.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT05660889
Study type Observational
Source Erasmus Medical Center
Contact Richard Feelders, Dr.
Phone +31107032861
Email r.feelders@erasmusmc.nl
Status Recruiting
Phase
Start date October 23, 2022
Completion date December 31, 2024
View Details
See also
  Status Clinical Trial Phase
Completed NCT04373265 - Study of Relacorilant in Combination With Pembrolizumab for Patients With Adrenocortical Carcinoma Which Produces Too Much Stress Hormone (Cortisol) Phase 1
Recruiting NCT06050057 - Surgical Treatment of Adrenal Diseases- Laparoscopic vs. Robotic-assisted Adrenalectomy
Recruiting NCT06066333 - Study of Radiotherapy and Pembrolizumab in People With Adrenocortical Carcinoma Phase 2
Recruiting NCT03127774 - Surgery and Heated Intraperitoneal Chemotherapy for Adrenocortical Carcinoma Phase 2
Completed NCT01048892 - Seneca Valley Virus-001 and Cyclophosphamide in Treating Young Patients With Relapsed or Refractory Neuroblastoma, Rhabdomyosarcoma, or Rare Tumors With Neuroendocrine Features Phase 1
Recruiting NCT00457587 - Preclinical Study Towards an Immunotherapy in Adrenocortical Carcinoma
Recruiting NCT00669266 - Adrenal Tumors - Pathogenesis and Therapy
Recruiting NCT05999292 - Phase 1 Study of 68Ga-R8760 Phase 1
Completed NCT05361083 - First-in-human Evaluation of [18F]CETO Early Phase 1
Completed NCT00003038 - Combination Chemotherapy With Suramin Plus Doxorubicin in Treating Patients With Advanced Solid Tumors Phase 1
Enrolling by invitation NCT03474237 - A Prospective Cohort Study for Patients With Adrenal Diseases
Recruiting NCT04119024 - Gene Modified Immune Cells (IL13Ralpha2 CAR T Cells) After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors Phase 1
Enrolling by invitation NCT05036434 - Phase II Trial of Pembrolizumab Plus Lenvatinib in Advanced Adrenal Cortical Carcinoma Phase 2
Terminated NCT05012397 - Milademetan in Advanced/Metastatic Solid Tumors Phase 2
Not yet recruiting NCT06333314 - Dostarlimab for Locally Advanced or Metastatic Cancer (Non-colorectal/Non-endometrial) With Tumor dMMR/MSI Phase 2
Withdrawn NCT00469469 - Treatment Study Using Bevacizumab for Patients With Adrenocortical Carcinoma Phase 2
Completed NCT00002608 - Combination Chemotherapy and Tamoxifen in Treating Patients With Solid Tumors Phase 2
Not yet recruiting NCT05839886 - The Adverse Event of Mitotane Therapy in Patients With Adrenocortical Carcinoma
Recruiting NCT05634577 - A Phase II Study to Evaluate the Efficacy and Safety of Pembrolizumab in Combination With Mitotane in Patients With Advanced Adrenocortical Carcinoma Phase 2
Completed NCT00454103 - Evaluation of 123I-Iodometomidate for Adrenal Scintigraphy Phase 1/Phase 2